Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, +21

Journal of Clinical Oncology

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, +251

The Lancet Oncology

First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine +5

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Robert J. Motzer, Bernard Escudier, Saby George, +28

Cancer

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N., +163

The Lancet

Platinum-based TherapyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine +6

Pretreatment Serum Testosterone Level as a Predictive Factor of Pathological Stage in Localized Prostate Cancer Patients Treated with Radical Prostatectomy

Takashi Imamoto, Hiroyoshi Suzuki, Satoshi Fukasawa, +6

European Urology

UrologyPredictive FactorGenitourinary CancerMedicineRadical Prostatectomy +4

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N., +141

The Lancet Oncology

Platinum-based TherapyUrologyGenitourinary CancerMedicineDocetaxel Versus Placebo +6

The Clinical Potential of Pretreatment Serum Testosterone Level to Improve the Efficiency of Prostate Cancer Screening

Masashi Yano, Takashi Imamoto, Hiroyoshi Suzuki, +5

European Urology

UrologyAndrologyClinical PotentialMedicineGynecology +5

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park, +175

Annals of Oncology

Metastatic Urothelial CancerUrologyGenitourinary CancerSelect Fgfr AlterationsMedicine +5

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study

Yoshihiko Tomita, Satoshi Fukasawa, Nobuo Shinohara, +12

Japanese Journal of Clinical Oncology

Combination of Gemcitabine and Paclitaxel as Second-line Chemotherapy for Advanced Urothelial Carcinoma

Takahito Suyama, Takeshi Ueda, Satoshi Fukasawa, +9

Japanese Journal of Clinical Oncology